NCT00000669View on ClinicalTrials.gov

A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Didanosine

Trial Locations (5)

35294

Univ of Alabama at Birmingham, Birmingham

38105

The Regional Medical Ctr, Memphis, Memphis

77030

Baylor College of Medicine, Houston

Univ TX Health Science Ctr, Houston

331361013

Univ of Miami School of Medicine, Miami

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000669 - A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection | Biotech Hunter | Biotech Hunter